News

PharmExec8h
LEO Pharma and Boehringer Ingelheim agree on $105 million deal for generalized pustular psoriasis (GPP) treatment Spevigo
Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...
LEO Pharma secures rights to Boehringer’s Spevigo for $105m
LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.
PharmiWeb5h
LEO Pharma Secures Global Rights to Spevigo in $105M Deal
LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...
pharmaphorum6h
LEO bulks up with deal for Boehringer skin drug
LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...
PipelineReview.com9h
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO® (spesolimab)
INGELHEIM, Germany & BALLERUP, Denmark I July 14, 2025 I Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer ...